DELTA-FLY PHARMA, INC.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 2010-12-06
- Employees
- 13
- Market Cap
- -
Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT06382168
- Locations
- 🇺🇸
UCI Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸University of Vermont Cancer Center, Burlington, Vermont, United States
Trial of DFP-14927 in Advanced Solid Tumors
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03943004
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸UCLA Department of Medicine- Hematology/Oncology, Los Angeles, California, United States
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT03926624
- Locations
- 🇺🇸
University of California, Irvine, California, United States
🇺🇸Decatur Memorial Hospital-Cancer Care Specialists of Central IL, Decatur, Illinois, United States
🇺🇸The University of Mississippi Medical Center, Jackson, Mississippi, United States
Phase I Study of Oral DFP-11207 in Solid Tumors
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT02171221
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study of DFP-10917 in Patients With Acute Leukemia
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2019-10-25
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT01702155
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath